-
Detailed recommendations for interactions with experimental COVID-19 therapies
-
World Health Organization releases advice for people living with HIV during the COVID-19 pandemic
-
COVID-19: British HIV Association updates guidance on vulnerable groups with HIV. People with HIV with CD4 <50 or recent opportunistic illness should follow shielding advice for the extremely vulnerable, statement says.
-
Long-acting injectable PrEP may offer an alternative to daily medication
-
HIV and COVID-19: BHIVA issues briefing. People with controlled HIV are not thought to be at increased risk, and there is no shortage of HIV medication, BHIVA says.
-
CROI 2020 – 6-week direct-acting antiviral therapy for acute hepatitis C infections ineffective Clinicians advised to stick with 12-week standard course
-
CROI 2020 – Every other month injectable HIV treatment effective but not ready for prime time Resistance, treatment failures cause for some concern
-
CROI 2020 – Point-of-care pre-exposure prophylaxis (PrEP) testing is here Test offers promising future for boosting PrEP adherence
-
Experts Facts summary on COVID-19 from CROI 2020
-
CROI 2020 – Single-tablet bictegravir+emtricitabine+tenofovir alafenamide non-inferior to dolutegravir-based regimens in older adults with HIV Phase 3 data highlight promising new regimen
-
CROI 2020 – COVID-19 transmission rate may be lower than expected Chinese data highlight value of isolation and containment
-
CROI 2020 – "London patient" remains HIV-free at 30 months Long-term HIV remission achievable
-
CROI 2020 – Tenofovir alafenamide–emtricitabine safety benefits do not justify cost vs tenofovir disoproxil fumarate–emtricitabine for HIV PrEP Consider access, cost before switching to new PrEP agent
-
CROI 2020 – Testosterone use in HIV-infected men conveys same cardiovascular risk seen in healthy men CROI 2020 – Monitor regularly and consider appropriate interventions
Latest Updates